Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients

Anti-Cancer Drugs

Volumn 9, Issue 2, 1998, Pages 125-129

  Boffetta, P ^a   Fichtinger Schepman, A M J ^b   Weiderpass, E ^a,c   Van Dijk Knijnenburg, H C M ^b   Stoter, G ^d   Van Oosterom, A T ^e   Keizer, H J ^f   Fossa S D ^g   Kaldor, J ^h   Roy, P ⁱ  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b TNO   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Radium Hospital   (Norway)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITÉ DE LYON   (France)

Author keywords

Cisplatin; DNA adducts; Protein bound platinum; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ADDUCT; DOSE TIME EFFECT RELATION; DRUG PROTEIN BINDING; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RELAPSE; TESTIS CANCER; TREATMENT OUTCOME;

EID: 6844254539     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199802000-00002     Document Type: Article

References (19)

1. Loehner PJ, Einhorn LH. Cisplatin. Ann Int Med 1984; 100: 704-13.
2. International Agency for Research on Cancer. Cisplatin. In: IARC monographs on the evaluation of the carcinogenic risks to humans, suppl. 7, overall evaluations of carcinogenicity: an updating of IARC Monographs Vols 1-42. Lyon: IARC 1987: 170-1.
3. Mead GM, Green JA, Macbeth FR, Williams CJ, Whitehouse JMA, Buchanan R. Second malignancy after cisplatin, vinblastin, and bleomycin (PVB) chemotherapy: a case report. Cancer Treat Rep 1983; 67: 410.
4. Pedersen-Bjergaard J, Rørth M, Avnstrøm S, Philip P, Hou-Jensen K. Acute nonlymphocytic leukemia following treatment of testicular cancer and gastric cancer with combination chemotherapy not including alkylating agents: report of two cases. Am J Hemat 1985; 18: 425-9.
5. Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst 1992; 84: 306-12.
6. Johnson NP, Butour JL, Villani G, et al. Metal antitumor compounds. The mechanism of action of platinum complexes. Prog Clin Biochem Med 1990; 10: 1-24.
7. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J. Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochem 1985; 24: 707-13.
8. Leng M, Brabec V. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs. In: Hemminki K, Dipple A, Shuker DEG, Kadlubar F, Bartsch H, eds. DNA adducts identification and biological significance (IARC scientific publications no 125). Lyon: IARC 1994: 339-48.
9. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Muta Res 1987; 190: 59-62.
10. Kaldor J, Schmähl D. Carcinogenicity of alkylating cytostatic drugs: conclusions for future research. In: Schmähl D, Kaldor JM, eds. Carcinogenicity of alkylating cytostatic drugs (IARC scientific publications no 78). Lyon: IARC 1986: 321-3.
11. Mustonen R, Hietanen P, Leppälä S, Takala M, Hemminki K. Determination of cis-diamminedichloroplatinum(II) in plasma proteins and hemoglobin of cancer patients. Arch Toxicol 1989; 63: 361-6.
12. SAS. Language, version 6, 1st edn. Cary, NC: SAS Institute Inc. 1990.
13. Perera FP, Motzer RJ, Tang D, et al. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res 1992; 52: 3558-65.
14. Fichtinger-Schepman AMJ, van der Velder-Visser SD, van Dijk-Knijnenburg HCM, van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990; 50: 7887-94.
15. Motzer RJ, Reed E, Perera F, et al. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 1994; 73: 2843-52.
16. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of cisplatin-DNA adduct level in testicular cancer patients. Carcinogenesis 1988; 9: 1909-11.
17. Reed E, Ozols RF, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acatl Sci 1987; 84: 5024-8.
18. Reed E, Ostchega Y, Steinberg SM, et al. Evaluation of platinum-DNA adduct levels relative to know prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 2256-60.
19. Gupta-Burt S, Shamkhani H, Reed E, et al. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prevent 1993; 2: 229-34.